Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
Provided By GlobeNewswire
Last update: May 14, 2025
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
Read more at globenewswire.com8.59
+0.53 (+6.58%)
Find more stocks in the Stock Screener
TERN Latest News and Analysis
